J 2021

Prevalence and Drivers of COVID-19 Vaccine Hesitancy among Czech University Students: National Cross-Sectional Study

RIAD, Abanoub, Andrea POKORNÁ, Natália ANTALOVÁ, Martin KROBOT, Nutsa ZVIADADZE et. al.

Základní údaje

Originální název

Prevalence and Drivers of COVID-19 Vaccine Hesitancy among Czech University Students: National Cross-Sectional Study

Autoři

RIAD, Abanoub (818 Egypt, garant, domácí), Andrea POKORNÁ (203 Česká republika, domácí), Natália ANTALOVÁ (703 Slovensko, domácí), Martin KROBOT (203 Česká republika, domácí), Nutsa ZVIADADZE (268 Gruzie, domácí), Iryna SERDIUK (804 Ukrajina, domácí), Michal KOŠČÍK (203 Česká republika, domácí) a Miloslav KLUGAR (203 Česká republika, domácí)

Vydání

Vaccines, Basel, MDPI, 2021, 2076-393X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30102 Immunology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 4.961

Kód RIV

RIV/00216224:14110/21:00122168

Organizační jednotka

Lékařská fakulta

UT WoS

000702106500001

Klíčová slova anglicky

COVID-19 vaccines; cross-sectional studies; Czech Republic; decision making; mass vaccination; university students; vaccine hesitancy

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 18. 10. 2021 10:32, Mgr. Tereza Miškechová

Anotace

V originále

Background: university students are believed to retain the highest levels of health literacy. They are perceived as the opinion leaders within their communities; therefore, their health-related beliefs and attitudes are deemed important for public health campaigns. This study aimed to investigate the COVID-19 vaccine hesitancy drivers among university students in the Czech Republic. Methods: a cross-sectional study using a self-administered questionnaire was carried out in the weeks before the unrestricted vaccine deployment to Czech adults. The questionnaire had 21 multiple-choice items stratified in 4 categories; demographic characteristics, COVID-19-related anamnesis and influenza vaccine experience, attitudes towards COVID-19 vaccination, and the possible drivers of COVID-19 vaccine hesitancy suggested by the WHO-SAGE. Results: out of the 1351 included students, 66.8% were females, 84.5% were Czech nationals, and 40.6% enrolled in healthcare programs. The overall COVID-19 vaccine acceptance level was 73.3%, 19.3% of participants were vaccine-resistant, and only 7.4% were vaccine-hesitant. Trust in the pharmaceutical industry, trust in healthcare providers, and perceived knowledge sufficiency predicted higher odds of vaccine acceptance. In contrast, media and social media, personal beliefs, immunity misconception, previous COVID-19 infection, and suspicions about novel vaccines and the local availability predicted higher odds of vaccine hesitancy. Conclusions: The findings of this study predict a fair probability to achieve community immunity (herd immunity) among the target population group. The primary prevention strategies in the Czech Republic need to be culturally sensitive and inclusive for foreign nationals. As one-quarter of the participating students are dependent on vaccine safety data, this study findings support the call for independent studies evaluating the side effects of COVID-19 vaccines.

Návaznosti

LTC20031, projekt VaV
Název: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic, INTER-COST
MUNI/A/1608/2020, interní kód MU
Název: Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu III
Investor: Masarykova univerzita, Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu III
MUNI/IGA/1543/2020, interní kód MU
Název: Evidence-based Practice of Healthcare Professionals and Students in the Czech Republic (Akronym: Evidence-Based Practice in Czechia)
Investor: Masarykova univerzita, Evidence-based Practice of Healthcare Professionals and Students in the Czech Republic